CANNABIS
Oromucosal route of delivering cannabis based medicine safe and effective in pain reduction
Neurology. 2005 Sep 27;65(6):812-966 patients with central neuropathic pain due to multiple sclerosis (MS) were randomly assigned to receive either cannabis-based medicine (CBM) through oromucosal spray or placebo for 4 weeks. Participants were assessed on pain severity, sleep disturbances, the impression of change, the incidence of adverse events, cognitive abilities, mood, and MS-related disability at the beginning and end of the study. Results demonstrated that oromucosal administration of CBM was effective in improving pain, sleep disturbance compared to placebo. The incidence of adverse events, cognitive abilities, mood, and disability were similar compared to placebo.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
